| Literature DB >> 26335519 |
Ashton J Engdahl1, Edith A Torres1, Sarah E Lock1, Taylor B Engdahl1, Pamela S Mertz1, Craig N Streu1.
Abstract
Combretastatin A4 is a stilbenoid tubulin binding mitotic inhibitor whose conformation greatly influences its potency, making it an excellent candidate for adaptation as a photoactivatable tool. Herein we report a novel synthesis, the facile isomerization with commercial grade equipment, and biological activity of azo-combretastatin A4 in vitro and in human cancer cells. Photoisomerized azo-combretestatin A4 is at least 200-fold more potent in cellular culture, making it a promising phototherapeutic and biomedical research tool.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26335519 DOI: 10.1021/acs.orglett.5b02262
Source DB: PubMed Journal: Org Lett ISSN: 1523-7052 Impact factor: 6.005